10 likes | 42 Views
The total incident cases of Acute Lymphocytic Leukemia in the 7MM were 10,341 in 2017. It is being observed that around 56% of age specific incident cases of ALL were found to be in the age group of <20 years in 2017. Also, ALL is more frequent in males as compared to females. <br><br>The market size of Acute Lymphocytic Leukemia in the 7MM was found to be USD 1,246 Million in 2017. <br><br>Increasing focus towards the development of targeted therapies, rising occurrence of ALL, improvement in the diagnosis and awareness, and competitive landscape are some of the key factors expected to drive the ALL market in the coming years. <br><br>The key players in the Acute Lymphocytic Leukemia market includes Pharmacyclics, Takara Bio/ Otsuka, Jazz Pharmaceutical, Bellicum Pharmaceuticals, Precision BioSciences, Allogene Therapeutics, Novartis, Autolus, Janssen Pharmaceuticals, Gamida Cell, BioLineRx, Bristol-Myers Squibb, Pfizer, Fate Therapeutics, Gilead Sciences, Sanofi, TCR2 Therapeutics, Miltenyi Biotec, AbbVie and others.<br><br>For more detailed information on Acute Lymphocytic Leukemia Market, visit: https://www.delveinsight.com/report-store/acute-lymphocytic-leukemia-all-market
E N D